HMGB1 and pemphigus foliaceus: Collectively, these results suggest that HMGB1 is a potential therapy target for PF and the inhibition of HMGB1 by PRM, neutralizing anti‐HMGB1 monoclonal antibody or PMX, might be effective for treating PF.